PCRX — Pacira BioSciences Inc. stock price and chart

PCRX

$36.38+0.11%

as of close, Oct 20, 2026

☾ AH $36.38 +0.11%

Pacira BioSciences Inc.Stock · HealthcareRussell 2000 · 0.03% of IWMRussell 3000 · 0.002% of IWVUS Stock Market · 0.001% of VTI

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEE

20162019202120242026

20.030.040.050.060.070.0020.0M40.0M$36.38

2026-10-20

Price$36.38

MA20$25.70

MA50$24.42

Vol5.1M

What would $1,000 invested in PCRX be worth today? →

PCRX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $36.38
YTD price return: +40.57%
YTD total return: +40.57%
Next earnings: Nov 5, 2026
Market cap: 1.5B2016-12 1.2B2026-10 1.5B+20.0% over the window
Enterprise value: 1.6B
Shares outstanding: 39.9M2016-06 37.3M2026-06 39.9M+6.9% over the window
52W low: $18.80
52W high: $36.67
From 52W high: -0.79%
From 52W low: +93.51%
52W range: 98%

Volume

Rel volume: 0.55×
30D volume: 1.9M
30D $ vol: 64.8M

Fundamentals

Sales (ttm): 746.2M2016-06 266.6M2026-06 746.2M+179.8% over the window
Sales/share: $18.722016-06 $7.152026-06 $18.72+161.7% over the window
EPS (ttm): $0.352016-06 -$0.292026-06 $0.35-220.8% over the window
FCF (ttm): 179.5M2016-06 -10.4M2026-06 179.5M-1829.9% over the window
FCF/share: $4.502016-06 -$0.282026-06 $4.50-1717.8% over the window
Book value/share: $16.862016-06 $6.132026-06 $16.86+175.2% over the window
Net margin: 1.96%2016-06 -4.2%2026-06 2.0%-146.6% over the window
ROE: 2.18%2016-06 -4.9%2026-06 2.2%-144.3% over the window
ROA: 1.18%2016-06 -2.8%2026-06 1.2%-142.0% over the window
Debt / equity: 0.54×2016-06 0.472026-06 0.54+16.0% over the window
Current ratio: 5.042016-06 1.712026-06 5.04+194.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +5.72%2025-06-30 → 2026-06-30705.8M → 746.2M (+5.7% total)+3.69%2023-06-30 → 2026-06-30669.2M → 746.2M (+11.5% total)+8.20%2021-06-30 → 2026-06-30503.1M → 746.2M (+48.3% total)+10.84%2016-06-30 → 2026-06-30266.6M → 746.2M (+179.8% total)
Net income: n/an/a-39.06%2021-06-30 → 2026-06-30174.1M → 14.6M (-91.6% total)n/a
FCF: +53.39%2025-06-30 → 2026-06-30117.1M → 179.5M (+53.3% total)+12.32%2023-06-30 → 2026-06-30126.7M → 179.5M (+41.7% total)+16.72%2021-06-30 → 2026-06-3082.9M → 179.5M (+116.6% total)n/a
Shares: -11.29%2025-06-30 → 2026-06-3044.9M → 39.9M (-11.3% total)-4.95%2023-06-30 → 2026-06-3046.4M → 39.9M (-14.1% total)-2.16%2021-06-30 → 2026-06-3044.5M → 39.9M (-10.3% total)+0.67%2016-06-30 → 2026-06-3037.3M → 39.9M (+6.9% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: n/an/a-38.39%2021-06-30 → 2026-06-30$3.91 → $0.35 (-91.1% total)n/a
Sales/share: +19.17%2025-06-30 → 2026-06-30$15.71 → $18.72 (+19.2% total)+9.09%2023-06-30 → 2026-06-30$14.42 → $18.72 (+29.8% total)+10.59%2021-06-30 → 2026-06-30$11.32 → $18.72 (+65.4% total)+10.10%2016-06-30 → 2026-06-30$7.15 → $18.72 (+161.7% total)
FCF/share: +72.91%2025-06-30 → 2026-06-30$2.61 → $4.50 (+72.8% total)+18.17%2023-06-30 → 2026-06-30$2.73 → $4.50 (+65.0% total)+19.30%2021-06-30 → 2026-06-30$1.86 → $4.50 (+141.6% total)n/a
Book value/share: -0.04%2025-06-30 → 2026-06-30$16.86 → $16.86 (-0.0% total)-1.06%2023-06-30 → 2026-06-30$17.41 → $16.86 (-3.2% total)+1.75%2021-06-30 → 2026-06-30$15.46 → $16.86 (+9.1% total)+10.65%2016-06-30 → 2026-06-30$6.13 → $16.86 (+175.2% total)
Price: +58.09%2025-10-20 → 2026-10-20$23.02 → $36.38 (+58.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.46%2023-10-20 → 2026-10-20$28.51 → $36.38 (+27.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-7.29%2021-10-20 → 2026-10-20$53.11 → $36.38 (-31.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+1.04%2016-10-19 → 2026-10-20$32.80 → $36.38 (+10.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +58.09%2025-10-20 → 2026-10-20$23.02 → $36.38 (+58.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+8.46%2023-10-20 → 2026-10-20$28.51 → $36.38 (+27.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-7.29%2021-10-20 → 2026-10-20$53.11 → $36.38 (-31.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+1.04%2016-10-19 → 2026-10-20$32.80 → $36.38 (+10.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 104.8×2016-12 -33.122026-10 99.07-399.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 73.0×2016-12 -39.772026-10 72.98-283.5% over the window
Fwd P/E: 10.5×
P/S (ttm)Market cap ÷ TTM revenue.: 1.9×2016-12 4.432026-10 1.94-56.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.2×2016-12 5.642026-10 2.16-61.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 8.1×2016-12 288.472026-10 8.08-97.2% over the window
EV/EBITDA (fy): 15.3×
EV/Sales (ttm): 2.2×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 12.38%2016-09 0.3%2026-06 17.8%+5020.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 39.9M ÷ 44.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 11.29%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (11.29%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 11.29%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($148.3M) ÷ today's market cap ($1.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 10.23%2016-09 0.0%2026-06 14.7%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $148.3M + TTM dividends $0) ÷ today's market cap ($1.5B). Same caveat as the cash buyback yield.: 10.23%2016-09 0.0%2026-06 14.7%

Vs own 10Y history

P/E: 63rd
P/OI: 71st
P/S: 25th
P/B: 32nd
P/FCF: 23rd

Bar = where today’s multiple sits in PCRX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+0.11%

+0.19%

+47.35%

+43.51%

YTD

+40.57%

+58.04%

-31.50%

Financial statements

Open full PCRX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

PCRX — Pacira BioSciences Inc. price, chart and key statistics